note eastern corridor
edit ny bo
pleasur host broad spectrum agil
manag team nyc boston post analyst
investor day tone consist construct frankli
time favor given recent volatil result mix
report key takeaway end follow market
overreact select cautiou commentari confer call
demand trend remain robust broadli china saw soft
small specif portion busi food outsiz share
overal growth remain hsd ldd idiosyncrat revenu driver
new product servic could sustain core growth msd
despit macro nois activ deploy balanc sheet
continu w/ mix repurchas bolt-on boost ep growth
high end peer mid high teen possibl sustain
patholog franchis continu despit threat liquid biopsi w/
lasergen invest open new complimentari avenu growth
oncolog pleas find detail note feel free
reach question
model updat tweak forecast account refin
view capit alloc take cash level also rais
pt modestli mid-teen ep compound-annual-growth-rate note still leav
net debt somewhat un-optim level due
view leverag like taken event larger bolt-on
transact vs sizeabl buy-back asr
continu next page
model updat chang price
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
eu us increasingli contribut growth w/ japan one laggard
bought stock right took advantag overreact within week
recur revenu year sinc acg effort began
 medium term goal well rang
digit transform marketplac huge benefit intern oper
util start ago key custom push
 materi portion busi whatsoev
 item typic requir much technic support handl
market misinterpret result management probabl messag cautious
 take blame overli transpar china
time report make comparison vs peer basi challeng
less sale today could consid digit natur
move upgrad financi system develop platform elimin redund part
discount move away increment smaller chang everi count price
varian exampl big bolt-on transact mike sponsor intern
forese major one-tim unlik prove bit messi
potenti upsid driver oil us pharma food/china dx notabl china
downsid risk europ obviou recent itali develop pmi
dd guidanc ep growth assum anti-dilut repurchas futur
open use balanc sheet right opportun either buy-back
outsiz cash balanc like also relat cash tax payment
actual access cash happen right post alreadi spent last week
remain exist repurchas author alreadi spoken
neg bia transform deal see anoth dako like deal know patholog time
focu area consum chemistri genom proteom oncolog informat
went assum debat go around didnt rais guid
growth skew given lunar new year
 overal revenu
believ slowdown food purchas like last month
 normal end calendar year
 prior exampl busi went post resumpt purchas
greater share equip vs peer group food
prepar suppli chain perspect trade war break unlik
gc main product manufactur china secondari mfg de
chang custom buy behavior due tariff
slight custom caution cycl time close order went
 mainli due raw materi inflat
servic china highest margin world highli valu low labor cost
china lsag dcg acg
chines govern remain highli focus develop analyt instrument remain far behind
 local competitor touch less market today
use wechat market fraction histor cost
countri level plan within exist china durat
hire employe last year base
leadership posit categori within lsag dgg broader
invest clean coal support gc momentum forese futur
 convers coal methan ga remain key focu govern
attach rate tend notabl higher corpor averag
price per slide function similar reagent rental model
 look increasingli lifetim custom valu
averag use life autostain year averag
 free guarante annual volum
nasd market growth remain
 start ramp
stori fulli play yet china market must open
 indic also like expand opportun
cdx strategi lasergen could competit box
busi overal current revenu
microfluid pull lsag move dgg biomolecular analysi
believ tissu biopsi remain preval decad come
liquid biopsi like addit market near term
nasd could contribut upsid core alon
 margin market product quit high risk develop
current capac nasd satisfi next year demand highli visibl
scale capac requir increment invest
lasergen sequenc hit certain metric
 math opportun grow market assum market share
central decis make order develop integr solut
full end market plan vs seri product build up longer tech driven
attach rate steadili rise new introduct
flexibl spend plan allow signific increment attach servic consum
 exampl next ms sale would add flex spend cross-sel
core rate consum current w/ averag margin
custom open handl tech refresh via oper leas
could see instrument servic long term saa lsag
lab manag increasingli realiz elong replac cycl neg product
lead liquid biopsi assay built sureselect target enrich engin
magnu load go system dna sheer prep librari
transact mani still done paper move digit
intuvo major upgrad requir lot face-to-fac time push product
 would actual character uptak plan
 still build ecosystem around box well
gc growth nearli dd base prior model
gc purchas tend conserv vs tradit buyer think cycl
ultivo run intern expect drive market share
 breadth end market adopt surpris broad appeal small footprint
intuvo per unit address instal base opportun
start see multi-unit replac intuvo vs
intuvo see best traction environment food contract manufactur
ultivo strong food environment pharma surpris
 overal spot w/ plan countri mix differ anticip
see underli shift market share
tough comp prior year also impact report
close market share larg key account especi petrochem think sinochem
 chemic energi remain
 overal explor highli sensit oil global growth
bake comp post tougher comp
sinc transform began
dgg omx constrain increment invest
invest launch lasergen
substanti upsid om core patholog
om busi upon day close improv
revenu signific enough lasergen nasd show upsid increment
move away point target increment target want flex also dont want aspir
volum leverag increment sale much less reliant histor
gap non-gaap rate cash tax
 report cash benefit could fulli off-set lasergen dilut
variabl comp highli sensit underli margin expans
evercor isi life scienc tool diagnosticsagil technolog stat million except per share data fy end decemb scienc appli market organ genom organ cross organ measurementtot organ gp less total scienc appli market genom cross op less ep share inc net inc price-to-earnings prem disc june
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin june et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
